Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

JOHNSON & JOHNSON

(JNJ)
  Report
Delayed Nyse  -  04:00 2022-09-27 pm EDT
164.94 USD   -0.46%
09/27Legend Biotech's Cancer Drug Carvykti Gets Japanese Approval to Treat Certain Adults with Multiple Myeloma
MT
09/22US Stocks End Lower Thursday Despite Healthcare Gains
MT
09/22US Stocks End Lower Thursday Despite Surge in Healthcare Shares
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nyse
09/21/2022 09/22/2022 09/23/2022 09/26/2022 09/27/2022 Date
163.28(c) 166.18(c) 166.72(c) 165.7(c) 164.94(c) Last
8 071 195 7 401 060 9 598 555 8 735 455 8 686 684 Volume
-1.02% +1.78% +0.32% -0.61% -0.46% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 95 525 M - -
Net income 2022 22 023 M - -
Net cash position 2022 9 791 M - -
P/E ratio 2022 20,2x
Yield 2022 2,65%
Sales 2023 98 982 M - -
Net income 2023 23 453 M - -
Net cash position 2023 22 323 M - -
P/E ratio 2023 18,3x
Yield 2023 2,80%
Capitalization 434 B 434 B -
EV / Sales 2022 4,44x
EV / Sales 2023 4,16x
Nbr of Employees 141 700
Free-Float 84,2%
More Financials
Company
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.5%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (28.9%): diagnostic systems,... 
Sector
Pharmaceuticals
Calendar
10/18Earnings Release
More about the company
Ratings of Johnson & Johnson
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about JOHNSON & JOHNSON
09/27Legend Biotech's Cancer Drug Carvykti Gets Japanese Approval to Treat Certain Adults wi..
MT
09/22US Stocks End Lower Thursday Despite Healthcare Gains
MT
09/22US Stocks End Lower Thursday Despite Surge in Healthcare Shares
MT
09/22Johnson & Johnson - Diversifying Our Health Workforce through the Impact of AIM
AQ
09/22Over 200 Inmates, Prison Officers Vaccinated Against Covid-19
AQ
09/21J&J's talc Texas two-step called out by victims
AQ
09/20No, Covid Vaccines Don't Cause Body to Produce Toxic Spike Proteins That Cause Cancer
AQ
09/20Johnson & Johnson Sets Up New R&D Facility in San Francisco Bay Area
MT
09/20Johnson & Johnson Opens State-of-the-Art Science and Technology Campus in San Francisco..
BU
09/20Johnson & Johnson Opens New R&D Facility in San Francisco Bay Area
DJ
09/19Johnson & Johnson : Debuts a Groundbreaking R&D Facility in the San Francisco Bay Area
PU
09/19US Stocks Turn Higher as Investors Await Fed Rate Decision on Wednesday
MT
09/19US Stocks Turn Higher as Investors Await Fed Rate Decision on Wednesday; 2-Year Bond Yi..
MT
09/19Vaccine Makers Fall After Biden Says 'Pandemic is Over'
MT
09/14Dow stabilizes following worst sell-off since 2020
AQ
More news
News in other languages on JOHNSON & JOHNSON
09/27Le médicament anticancéreux Carvykti de Legend Biotech obtient l'approbation du Japon p..
09/26Wall Street en ordre dispersé, la nervosité prend le dessus
09/26ANALYSEN DES TAGES von Dow Jones Newswires (26.09.2022)
09/24Enquête en France sur des implants vaginaux pour tromperie et blessures
09/22Les actions américaines terminent en baisse jeudi malgré des gains dans le secteur de l..
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
ETFs positioned on JOHNSON & JOHNSONETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Nomura NEXT FUNDS International Equity MSCI...12.91%-5.63%-World
HSBC USA SUSTAINABLE EQUITY - Acc - USD11.52%-4.33%-United_States
HSBC USA SUSTAINABLE EQUITY UCITS (dist) ETF - USD10.57%-4.36%-United_States
IShares U.S. Healthcare ETF - USD9.36%-3.65%-NC
SPDR S&P U.S. Health Care Select Sector - USD9.17%-2.37%United_States
More ETFs positioned on JOHNSON & JOHNSON
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 164,94 $
Average target price 185,07 $
Spread / Average Target 12,2%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
Alex Gorsky Executive Chairman
Peter Shen Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON-3.58%433 657
ELI LILLY AND COMPANY11.32%292 179
ROCHE HOLDING AG-19.31%253 262
ABBVIE INC.4.29%249 673
PFIZER, INC.-25.33%245 989
MERCK & CO., INC.12.00%218 318